



## Thomas Weisel Partners

*Experts in Growth*

### THOMAS WEISEL PARTNERS HOSTS ANNUAL HEALTHCARE CONFERENCE

**Boston, MA, September 9, 2009** – Thomas Weisel Partners (NASDAQ: TWPG), a global growth-focused investment bank, will host its Annual Healthcare Conference, September 9-11 at the Four Seasons Hotel in Boston. Institutional investors and company management will gather for this three-day conference, which will focus on opportunities and challenges in the healthcare industry for the remainder of 2009 and beyond.

The conference will showcase presentations from 200 established and emerging public and private companies, including those engaged in biotechnology, diagnostics, healthcare information technology, healthcare services, pharmaceutical services, life science tools, medical devices and specialty pharmaceuticals.

“We remain committed to focused coverage of Healthcare, one of the most important areas of growth in the U.S. economy. Despite broad economic weakness over the last year, healthcare spending continues to increase as a percentage of GDP. Aggregate healthcare spending is expected to reach 20% by 2018, up from 16% in 2008. Accordingly, many healthcare companies continue to show signs of significant growth with solid performance and we believe long-term healthcare demand trends remain positive,” said Keith Gay, Head of TWP’s Research Group.

The conference commences Wednesday morning and will be led by Thomas Weisel Partners seven senior health care research analysts: Raj Denhoy, medical devices; Alan Fishman, healthcare services; Steven Halper, healthcare information technology and pharmaceutical services; Peter Lawson, life science tools and diagnostics; Annabel Samimy, specialty pharmaceuticals; Ian Somaiya, biotechnology; and Stephen Willey, biotechnology. Analysts will offer insight into the major trends impacting their respective sectors.

A full list of company participants includes:

|                                       |                                |
|---------------------------------------|--------------------------------|
| Acclarent, Inc.                       | Amira Pharmaceuticals          |
| Achillion Pharmaceuticals             | Anadys Pharmaceuticals, Inc.   |
| Advanced Pharmacy                     | Ardea Biosciences, Inc.        |
| Aegerion Pharmaceuticals, Inc.        | Array BioPharma Inc.           |
| Affymax, Inc.                         | Arstasis                       |
| Affymetrix, Inc.                      | athenahealth, Inc.             |
| Agilent Technologies, Inc.            | Atritech, Inc.                 |
| Alder Biopharmaceuticals Inc.         | AutoGenomics, Inc.             |
| Alexion Pharmaceuticals, Inc.         | Auxilium Pharmaceuticals, Inc. |
| Alkermes, Inc.                        | Avanir Pharmaceuticals         |
| Allergan, Inc.                        | Beckman Coulter, Inc.          |
| Allscripts Healthcare Solutions, Inc. | Becton, Dickinson and Company  |
| Alnylam Pharmaceuticals, Inc.         | Bio-Rad Laboratories, Inc.     |
| Alphatec Holdings, Inc.               | Biogen Idec Inc.               |
| Ambit Biosciences                     | Biolex Therapeutics            |
| Ambrx                                 | BioMarin Pharmaceutical, Inc.  |
| Amgen, Inc.                           | Biovail Corporation            |

Boston Scientific Corporation  
Bruker Corporation  
CambridgeSoft Corporation  
Cardinal Health, Inc.  
Cardiovascular Systems, Inc.  
Celator Pharmaceuticals, Inc.  
Celera Corporation  
Celgene Corporation  
Cephalon, Inc.  
Cepheid  
Cerner Corporation  
Concert Pharmaceuticals Inc.  
CONMED Corporation  
Corcept Therapeutics Incorporated  
Cornerstone Therapeutics, Inc.  
CorNova, Inc.  
Covance Inc.  
Cubist Pharmaceuticals, Inc.  
CVS Caremark Corporation  
Cytochroma Inc.  
dbMotion Ltd.  
Devax, Inc.  
diaDexus, Inc.  
Dicerna Pharmaceuticals, Inc.  
Dionex Corporation  
Discovery Laboratories, Inc.  
Dyax Corp.  
eBioscience  
Eclipsys Corporation  
EGEN, Inc.  
eHealth, Inc.  
EKR Therapeutics, Inc.  
Endo Pharmaceuticals  
Enzo Biochem, Inc.  
Eurand (US)  
ev3 Inc.  
Exactech, Inc.  
Exagen Diagnostics, Inc.  
Exelixis, Inc.  
Exiqon A/S  
Express Scripts, Inc.  
Facet Biotech Corporation  
Fluidigm Corporation  
ForteBio  
Gen-Probe Incorporated  
Genomic Health, Inc.  
Genzyme Corporation  
Geron Corporation  
Gilead Sciences, Inc.  
GlobeImmune, Inc.  
Hill-Rom Holdings, Inc.  
Human Genome Sciences, Inc.  
Icagen, Inc.  
Idenix Pharmaceuticals, Inc.  
Ikonisys Inc.  
Illumina Inc.  
ImmunoGen, Inc.  
IMS Health Incorporated  
Insulet Corporation  
Integra LifeSciences Corporation  
InterMune, Inc.  
Interventional Spine, Inc.  
ISIS Pharmaceuticals, Inc.  
Kinetic Concepts, Inc.  
Knome, Inc.  
LDR Spine  
Lexicon Pharmaceuticals, Inc.  
Ligand Pharmaceuticals Inc.  
Light Sciences Oncology Inc.  
Lincare Holdings Inc.  
Luminex Corporation  
Lux Biosciences, Inc.  
MacroGenics Inc.  
MAKO Surgical Corp.  
MAP Pharmaceuticals Inc.  
Masimo Corporation  
McKesson Corporation  
MedAptus, Inc.  
Medco Health Solutions, Inc.  
Medicis  
MEDNAX, Inc.  
Merit Medical Systems, Inc.  
Merrimack Pharmaceuticals, Inc.  
Millipore Corporation  
Natus Medical Incorporated  
NeurAxon Inc.  
Neurocrine Biosciences, Inc.  
Neuronetics, Inc.  
NuVasive, Inc.  
Obagi Medical Products, Inc.  
Omnicare, Inc.  
Omniceil, Inc.  
OmniGuide, Inc.  
OncoGenex Pharmaceuticals Inc  
Onyx Pharmaceuticals  
Optimer Pharmaceuticals, Inc.  
Orthofix International N.V.  
OSI Pharmaceuticals Inc  
Owens & Minor, Inc.  
Paratek Pharmaceuticals, Inc.  
PAREXEL International Corporation  
PatientKeeper, Inc.  
PEAK Surgical  
Penwest Pharmaceuticals Co.  
PerkinElmer, Inc.  
Pharmaceutical Product Development, Inc.  
Pharmacyclics, Inc.  
Phase Forward Incorporated  
Picis, Inc.  
POZEN Inc.

Psychiatric Solutions, Inc.  
Qiagen N.V.  
Quality Systems, Inc.  
RainDance Technologies  
Reata Pharmaceuticals, Inc.  
Regado Biosciences, Inc.  
Regulus Therapeutics Inc.  
RehabCare Group, Inc.  
Revance Therapeutics, Inc.  
Rib-X Pharmaceuticals, Inc.  
Rigel Pharmaceuticals, Inc.  
ROXRO PHARMA, Inc.  
RTI Biologics Inc.  
S\*BIO Pte Ltd.  
Salient Surgical Technologies, Inc.  
Salix Pharmaceuticals, Ltd.  
Santarus, Inc.  
Seattle Genetics, Inc.  
SenoRx, Inc.  
Sepracor Inc.  
Sigma-Aldrich Corporation  
SonoSite, Inc.  
St. Jude Medical, Inc.  
StemCells, Inc.  
superDimension, Inc.

Symmetry Medical, Inc.  
T2 Biosystems, Inc.  
Teleflex Incorporated  
The Cooper Companies, Inc.  
Theravance, Inc.  
Thermo Fisher Scientific Inc.  
TomoTherapy Incorporated  
TranS1, Inc.  
Transdel Pharmaceuticals, Inc.  
Tranzyme Pharma  
USGI Medical  
Vertex Pharmaceuticals Inc.  
Vical Incorporated  
ViroPharma Incorporated  
VisualSonics Inc.  
Vitae Pharmaceuticals  
Vital Images, Inc.  
Vivus, Inc.  
Volcano Corporation  
Waters Corporation  
Wright Medical Group, Inc.  
XDx  
Xoft, Inc.  
Zimmer Holdings, Inc.  
ZymoGenetics, Inc.

### **About Thomas Weisel Partners Group, Inc.**

Thomas Weisel Partners Group, Inc. is an investment bank, founded in 1998, focused principally on the growth sectors of the economy. Thomas Weisel Partners Group, Inc. generates revenues from three principal sources: investment banking, brokerage and asset management. The investment banking group is comprised of two disciplines: corporate finance and strategic advisory. The brokerage group provides equity and convertible debt securities sales and trading services to institutional investors, and offers brokerage, advisory and cash management services to high-net-worth individuals and corporate clients. The asset management group consists of: private equity, public equity and distribution management. Thomas Weisel Partners is headquartered in San Francisco with additional offices in Baltimore, Boston, Calgary, Chicago, Denver, New York, Portland, Toronto, London and Zurich. For more information, please visit [www.tweisel.com](http://www.tweisel.com).

#### Investor Relations Contact:

Sarah Anderson  
415-364-2500  
[investorrelations@tweisel.com](mailto:investorrelations@tweisel.com)

#### Media Contact:

Crystal Odessky  
415-364-2500  
[codessky@tweisel.com](mailto:codessky@tweisel.com)